Latest in NHS

Destiny Pharma receives US FDA QIDP designation for novel antibacterial product

Lead drug product in development for the prevention of post-surgical Staphyloccocal infections

Find out more

Ensuring drug safety using AI models for adverse drug reaction prediction

Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide
See more

Sustainability that performs: how GEA is building a better future for pharma

By embedding ESG principles into pharmaceutical manufacturing, GEA is delivering measurable sustainability performance without compromising compliance or productivity